ASTCT Practice Guidelines "Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy (Revision)”

Program Description: Articles designated for CME credit are designed to be the next step in the process of translating clinically relevant, evidence-based recommendations into clinical practice. This will be accomplished through a series of questions specifically designed to test that readers have the tools needed to translate recommendations for diagnostic and therapeutic clinical care into clinical practice. Post-test questions will assess if practitioners have understood the most important recommendations available for the diagnosis and treatment of pulmonary diseases, critical illness, and sleep disorders, and are able to implement them into clinical practice. Each Journal CME activity consists of the full-text article, a post-test quiz, and a course evaluation. Each CME activity should take approximately 1 hour to complete. This is an online-only activity.

Article Description: The field of immune effector cell therapy (ICET) is rapidly expanding with multiple FDA approval of several  CAR-T products in the recent years and  evolving indications for these in patients with hematologic malignancies and blood disorders. Due to the expansion of knowledge in this field, the (ASTCT has put together focus guidelines for indication for currently FDA approved CAR-T products.  This paper outlines these indications guidelines which can serve as a reference tool for community Oncologist, IECT centers, payers and policy makers for appropriate use of these products. It is anticipated that there will more iterations of these guidelines are more products get approved in the future. 

Learning Objectives: Upon completion of this course, the learners should be able to:

1. Explain that the updated 2023 Guidelines for IEC serve as a supervisory framework for patients, physicians, payers, and policy makers and not to determine optimal therapeutic strategies
2. Describe the current indication for FDA approved IEC Products

Target Audience: This educational activity is intended for physicians, nurses, and other members of the health care team who care for patients undergoing hematopoietic stem cell transplantation.

Instructions for Participation and Requesting Credit: There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CME information, completing the activity, and completing the post-test and evaluation form. A posttest score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed. Once the test is passed, participants will be asked to fill out a program evaluation in order to download the CME Certificate. The CME Certificate will be available for download at the same link in the ASTCT Learning Center once the evaluation has been submitted. By completing this evaluation, you grant ASTCT permission to report your participation to the ACCME and that you grant the ACCME permission to share the learner data that ASTCT reports with the learner's state medical licensing board(s) and/or specialty certifying board(s). If you have any concerns about these permissions, please email info@astct.org.

Technical Requirements: This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers. Additionally, this site and its activities are best viewed using the latest Operating System for your device.

If you have any questions about this course, please reach out to info@astct.org.

ACCREDITED PROVIDER 

This activity is provided by The American Society for Transplantation and Cellular Therapy

Accreditation Statement: In support of improving patient care, The American Society for Transplantation and Cellular Therapy is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society for Transplantation and Cellular Therapy designates this journal-based activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release date: March 12, 2024

Expiration date: July 1, 2024

Estimated time of completion: 1 hour

Learning Objectives: Upon completion of this activity, the learners should be able to:

1. Explain that the updated 2023 Guidelines for IEC serve as a supervisory framework for patients, physicians, payers, and policy makers and not to determine optimal therapeutic strategies
2. Describe the current indication for FDA approved IEC Products

Target Audience: This educational activity is intended for physicians, nurses, and other members of the health care team who care for patients undergoing hematopoietic stem cell transplantation.

Planning Faculty and Disclosures: In accordance with the ACCME Standards for Commercial Support the American Society for Transplantation and Cellular Therapy (ASTCT) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial entity. ASTCT resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

• Hemalatha Rangarajan, MD, Nationwide Children’s Hospital – reported no relevant financial relationships. 
• Reshma Ramlal, MD, University of Kentucky – reported no relevant financial relationships.
• Kyra Newman, ASTCT - reported no relevant financial relationships.

Commercial Support Acknowledgment: This activity did not receive commercial support.

Disclaimer: ASTCT presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. ASTCT assumes no liability for the information herein.

Disclosure of Unlabeled Use: ASTCT requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ASTCT does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.